Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
KEPIVANCE |
| Manufacturer |
|
Amgen, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Keratinocyte growth factor (recombinant). |
| Generic Name |
|
Palifermin 6.25mg/vial; pwd for IV inj after reconstitution; preservative-free; contains mannitol. |
| Indications |
|
To decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. |
| Children |
|
Not recommended. |
| Adults |
|
See literature. Give as IV bolus inj for 6 doses total. 60micrograms/kg per day for 3 consecutive days before myelotoxic therapy (give 3rd dose 24–48 hrs before myelotoxic therapy); then 60micrograms/kg per day for 3 consecutive days starting at least 24 hours after myelotoxic therapy (give 1st dose after, but on same day as, hematopoietic stem cell infusion, at least 4 days after last palifermin dose). |
| Precautions |
|
Non-hematologic malignancies. Elderly. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
May bind heparin; if heparin is used to maintain IV line, rinse line with saline before and after palifermin use. |
| Adverse Reactions |
|
Skin or oral toxicities (eg, rash, erythema, edema, pruritus, dysesthesia, dysgeusia, tongue discoloration/ thickening), arthralgia, fever, GI upset, respiratory events, antibody formation. |
| How Supplied |
|
Single-use vials—6 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
